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a b s t r a c t
This case report demonstrates efﬁcacy of topical timolol for the treatment for residual IH
in the facial area in a child, previously treated with propranolol. The treatment was well
tolerated. Local or systemic side effects were not seen. Conclusion: Timolol gel is an
effective therapy option for residual hemangiomas, and should be considered as
a complementary treatment for residual hemangiomas after terminating propranolol
treatment.
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Fig. 1 – Patient before the treatment
Ryc. 1 – Pacjent przed leczeniem
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Infantile hemangiomas (IH) are neoplastic proliferations of
endothelial cells, which grow after birth and usually regress
spontaneously [1]. IH occur with an incidence of 10–12%
within the ﬁrst year of life, and female infants are three to
four times more likely to suffer from IH as male infants [2].
IH can lead to deformities when they are located in the
facial areas of the lip, nasal tip or the ear. IH can be life-
threatening when present in the upper airways, brain and
liver, by inducing acute respiratory failure and congestive
heart failure [1, 2]. Tumor involvement can be superﬁcial,
deep, or mixed. The majority of IH enlarge over 6–9 months
and then spontaneously involute over 2–10 years. It is
difﬁcult to assess whether IH will continue growing or
regress spontaneously. Often there are residual ﬁndings
[1, 2]. Although the majority of residual IH are aesthetically
insigniﬁcant, but still may be the cause of parents concern if
in visible locations. The treatment of even small heman-
gioma in the facial area should be considered, as it is not
possible to predict the outcome, and they are associated
with parental distress. Currently there are not many thera-
peutic options. Corticosteroids have been the ﬁrst-line
agents for systemic treatment for IH. Recently oral propra-
nolol, a non-selective beta-blocker, has emerged as an
alternative in the treatment of IH [1, 2]. Corticosteroids and
propranolol both may have signiﬁcant systemic adverse
effects [3, 4]. A limited number of topical agents have been
adapted for treatment of IH – corticosteroids and imiquimod
[5]. Small IH were also treated by pulse dye laser (PDL) [5].
Recently, timolol maleate gel, a topical nonselective beta-
blocker has been reported as a potential new topical agent
for superﬁcial IH [6]. We present a case report of multisite,
facial, superﬁcial IH treated with propranolol and its resi-
dual treated successfully with timolol maleate gel.Fig. 2 – Patient after oral propranolol treatment
Ryc. 2 – Pacjent po doustnym leczeniu propranololemCase report
A baby girl with multiple, facial hemangiomas presented to
our department at the age of 2 months. The hemangiomas
were superﬁcial and located on the eyelids, on the tip of the
nose, on the upper lip and in the temporal area of the
forehead (Fig. 1). A physical examination of the girl was
performed before the start of the therapy in order to exclude
other illnesses and rule out treatment contraindications. An
echocardiography was performed and blood pressure was
taken. With the written consent of both parents, at the
beginning the girl was treated with propranolol. During
three consecutive days dosage of propranolol was gradually
increased to 3 mg/kg. During ambulatory surveillance of the
girl, potassium, sodium, chlorine, glucose, liver enzymes,
morphology, vital signs and ECG were monitored. The
hemangiomas slowly diminished in size. After 6 months of
treatment the dose of propranolol was reduced to 2 mg/kg.
After next 2 months of treatment the dose was reduced to
1 mg/kg. The treatment was terminated after 10 months at
the age of 1 year. Still there were residual hemangiomas on
the upper lip, tip of the nose and forehead, and were thecause of parents concern (Fig. 2). At the age of 1 year and
3 months the treatment with timolol maleate gel was
started. Timolo gel was applied twice a day by rubbing
carefully on the hemangiomas, for a period of 2 months,
and once a day for a period of one month. Before the start
of the timolol therapy, pictures of the hemangiomas were
taken. No side effects were reported by the parents, and the
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Fig. 3 – Patient after topical treatment with timolol
Ryc. 3 – Pacjent po miejscowym leczeniu timololem
p e d i a t r i a p o l s k a 8 8 ( 2 0 1 3 ) 1 1 6 – 1 1 9118follow-up examination of the girl, which included electro-
cardiography as well as a measurement of blood pressure,
were unremarkable. After three-month treatment the result
was excellent (Fig. 3). Response to timolol treatment was
stable over time. After one year surveillance, at the age of
2.5 year there are no traces of facial hemangiomas in our
patient.Discussion
In 2008, Leaute-Labreze et al. reported the incidental ﬁnding
that IH regress in children treated with propranolol,
a nonselective beta-blocker used in treating infants with
cardiac and renal conditions [7]. In most case reports,
propranolol was not used as a single therapy of IH, patients
received concomitant systemic or intralesional steroids and
laser treatment [8]. Schiestl et al. in their study included
only infants with IH treated exclusively with propranolol at
a dose of 2 mk/kg/day, and in all patients there was
a signiﬁcant cosmetic improvement [9].The effect of propranolol on IH can be attributed to
molecular mechanisms: vasoconstriction, decreased expres-
sion of vascular endothelial growth factor (VEGF) and basic
ﬁbroblast growth factor (bFGF) genes through the down-
regulation of the RAF-mitogen-activated protein kinase
pathway, inhibition of angiogenesis, and induction of apop-
tosis [9]. Treatment with propranolol may cause severe
systemic complications and infants need to be closely
monitored [1, 2, 4, 5, 7–9]. During propranolol therapy of our
patient, potassium, sodium, chlorine, glucose, liver enzy-
mes, morphology, vital signs and ECG were monitored. The
most common reported side effects of propranolol include
hypotension, bradycardia, hypoglycemia and bronchospasm
[1, 2, 4, 5, 7–9]. Moreover propranolol may mask the clinical
signs of early cardiac failure, diminish cardiac performance,
and blunt clinical features of hypoglycemia. Prolonged
hypoglycemia in infancy is associated with neurologic
sequelae [1]. During ambulatory surveillance we did not
observe hypoglycemia, hypotension or adverse cardiac
effects. The treatment was well tolerated.
For small, superﬁcial IH treatment options are: intralesio-
nal steroids, PDL treatment, topical steroids, imiquimod 5%
cream and topical propranolol hydrochloride or timolol
maleate [6].
Several studies indicate that topical timolol gel is effec-
tive and safe for the treatment of IH and can an alternative
or complementary to systemic propranolol [10]. Topical
timolol is effective not only in stopping hemangioma
growth, but also causes decreased tumor volume [10].
Guo and Ni were the ﬁrst who reported the positive
effects of the use of topical timolol in treating capillary IH in
a 4-month-old infant [10]. At the World Congress of Paedia-
tric Dermatology in Bangkok in 2009, Pope and Chakkiiakan-
diyil [11] reported on a pilot study showing that topical
timolol had successful effect in the treatment of superﬁcial
IH. Timolol does not penetrate deeply and can be only used
in superﬁcial IH. The mechanism of action is not clear, but
presumably is the same as for propranolol [6]. The advanta-
ges of topical tomolol are low cost, ease of administration,
and minimal risk of drug-related adverse events. Several
case reports connect wheezing, bradycardia, and respiratory
depression, especially in infants with the long-term use of
timolol ocular solution [3]. Also several cases of contact
allergy to timolol and related drugs have been described [6].
No side effects were observed in our patient. After three-
month treatment the result was excellent, and response to
timolol treatment was stable over time. Ophtalmic timolol
gel has been shown to have less or insigniﬁcant systemic
bioavailability than timolol ophthalmic solution [3]. Small
residual IH in the facial area are not an indication for
treatment, but in our case were the source of parents
concern. We think, that in the case of any visible abnorma-
lities in the facial area, as far as IH are concerned, there is
a certain necessity for treatment.Conclusion
Timolol gel is an effective therapy option for residual heman-
giomas, and should be considered as a complementary
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